Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 160

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 160
---
194,030 | ) |     |     |    (228,191 | ) |     |          |               (5,217,373 | ) |
| TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                                                                                                         |     | $                    |                  177,611 |   |     |     |    (221,374 | ) |     | $        |                  161,084 |   |

| 125 |

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information known to the Company with respect to the beneficial ownership of each class of the Company’s capital stock as of August 13, 2025 for (1) each person known by the Company to beneficially own more than 10% of each class of the Company’s voting securities, (2) each executive officer, (3) each of the Company’s directors and (4) all of the Company’s executive officers and directors as a group.

Based on 33,554,705 shares issued and outstanding

| Title of Class |     | Name and Address of Beneficial Owner  |     | Amount and Nature of Beneficial Ownership |           |   |     | Percentage |    |   |
| Common         |     | David R. Koos                         |     |                                           | 7,436,799 | * |     |            | 22 | % |
|                |     | c/o Regen Biopharma, Inc.             |     |                                           |           |   |     |            |    |   |
|                |     | 4700 Spring Street St 304             |     |                                           |           |   |     |            |    |   |
|                |     | La Mesa CA 91942*                     |     |                                           |           |   |     |            |    |   |
| Common         |     | All Officers and Directors as a Group |     |                                           | 7,436,799 | * |     |            | 22 | % |

*includes 19 shares held by BMXP Holdings Shareholder’s Business Trust and 11 shares held by the AFN Trust and 366,651 shares held by Zander Therapeutics, Inc.

Based on 10,123,771 shares issued and outstanding

| Title of Class     |     | Name and Address of Beneficial Owner  |     | Amount and Nature of Beneficial Ownership |         |     | Percentage |      |